These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2036 related items for PubMed ID: 16870085

  • 1. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 2. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 3. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Jul; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ.
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
    Ryan PD, Goss PE.
    Oncologist; 2006 Jun; 11(7):718-31. PubMed ID: 16880231
    [Abstract] [Full Text] [Related]

  • 9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 10. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
    van de Velde CJ, Verma S, van Nes JG, Masterman C, Pritchard KI.
    Cancer Treat Rev; 2010 Feb 10; 36(1):54-62. PubMed ID: 19944537
    [Abstract] [Full Text] [Related]

  • 11. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.
    Curr Med Res Opin; 2006 Aug 10; 22(8):1575-85. PubMed ID: 16870082
    [Abstract] [Full Text] [Related]

  • 12. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT, Robert NJ.
    Eur J Cancer; 2005 Aug 10; 41(12):1678-89. PubMed ID: 16098456
    [Abstract] [Full Text] [Related]

  • 13. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT.
    Breast Cancer Res Treat; 2008 Dec 10; 112 Suppl 1():25-34. PubMed ID: 19101792
    [Abstract] [Full Text] [Related]

  • 14. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G.
    Oncol Nurs Forum; 2008 Jul 10; 35(4):714-21. PubMed ID: 18591176
    [Abstract] [Full Text] [Related]

  • 15. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT.
    Breast; 2008 Apr 10; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [Abstract] [Full Text] [Related]

  • 16. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU, Cuzick J.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant aromatase inhibitor therapy: outcomes and safety.
    Janni W, Hepp P.
    Cancer Treat Rev; 2010 May 01; 36(3):249-61. PubMed ID: 20133065
    [Abstract] [Full Text] [Related]

  • 18. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Abdulhaq H, Geyer C.
    Am J Clin Oncol; 2008 Dec 01; 31(6):595-605. PubMed ID: 19060594
    [Abstract] [Full Text] [Related]

  • 19. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [Abstract] [Full Text] [Related]

  • 20. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.
    Cancer; 2006 Jun 15; 106(12):2576-82. PubMed ID: 16703595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 102.